Literature DB >> 17671222

Down-regulation of the sodium/iodide symporter explains 131I-induced thyroid stunning.

Madeleine M Nordén1, Fredrik Larsson, Sofia Tedelind, Therese Carlsson, Charlotta Lundh, Eva Forssell-Aronsson, Mikael Nilsson.   

Abstract

(131)I radiation therapy of differentiated thyroid cancer may be compromised by thyroid stunning (i.e., a paradoxical inhibition of radioiodine uptake caused by radiation from a pretherapeutic diagnostic examination). The stunning mechanism is yet uncharacterized at the molecular level. We therefore investigated whether the expression of the sodium/iodide symporter (NIS) gene is changed by irradiation using (131)I. Confluent porcine thyroid cells on filter were stimulated with thyroid-stimulating hormone (TSH; 1 milliunit/mL) or insulin-like growth factor-I (IGF-I; 10 ng/mL) and simultaneously exposed to (131)I in the culture medium for 48 h, porcine NIS mRNA was quantified by real-time reverse transcription-PCR using 18S as reference, and transepithelial iodide transport was monitored using (125)I(-) as tracer. TSH increased the NIS expression >100-fold after 48 h and 5- to 20-fold after prolonged stimulation. IGF-I enhanced the NIS transcription at most 15-fold but not until 5 to 7 days. (131)I irradiation (7.5 Gy) decreased both TSH-stimulated and IGF-I-stimulated NIS transcription by 60% to 90% at all investigated time points. TSH and IGF-I stimulated NIS synergistically 15- to 60-fold after 5 days. NIS expression was reduced by (131)I also in costimulated cells, but the transcription level remained higher than in nonirradiated cells stimulated with TSH alone. Changes in NIS mRNA always correlated with altered (125)I(-) transport in cultures with corresponding treatments. It is concluded that down-regulation of NIS is the likely explanation of (131)I-induced thyroid stunning. Enhanced NIS expression by synergistically acting agents (TSH and IGF-I) partly prevents the loss of iodide transport expected from a given absorbed dose, suggesting that thyroid stunning might be pharmacologically treatable.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17671222     DOI: 10.1158/0008-5472.CAN-07-0823

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  17 in total

1.  Effects of varying dietary iodine supplementation levels as iodide or iodate on thyroid status as well as mRNA expression and enzyme activity of antioxidative enzymes in tissues of grower/finisher pigs.

Authors:  Qimeng Li; Christiane Mair; Karl Schedle; Isabella Hellmayr; Wilhelm Windisch
Journal:  Eur J Nutr       Date:  2012-01-07       Impact factor: 5.614

Review 2.  The sodium iodide symporter (NIS): regulation and approaches to targeting for cancer therapeutics.

Authors:  Takahiko Kogai; Gregory A Brent
Journal:  Pharmacol Ther       Date:  2012-06-29       Impact factor: 12.310

3.  Mean and maximum standardized uptake values in [18F]FDG-PET for assessment of histopathological response in oesophageal squamous cell carcinoma or adenocarcinoma after radiochemotherapy.

Authors:  Matthias Schmidt; Elfriede Bollschweiler; Markus Dietlein; Stefan P Mönig; Carsten Kobe; Daniel Vallböhmer; Daniel Vallboehmer; Wolfgang Eschner; Arnulf Hölscher; Harald Schicha
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-12-19       Impact factor: 9.236

4.  Correction for hyperfunctioning radiation-induced stunning (CHRIS) in benign thyroid diseases.

Authors:  C Happel; W T Kranert; D Gröner; B Bockisch; A Sabet; I Vardarli; R Görges; K Herrmann; F Grünwald
Journal:  Endocrine       Date:  2020-03-16       Impact factor: 3.633

5.  Thyroid stunning in radioiodine-131 therapy of benign thyroid diseases.

Authors:  Christian Happel; Wolfgang Tilman Kranert; Hanns Ackermann; Ina Binse; Benjamin Bockisch; Daniel Gröner; Ken Herrmann; Frank Grünwald
Journal:  Endocrine       Date:  2018-12-31       Impact factor: 3.633

6.  Decrease in thyroid adenoma associated (THADA) expression is a marker of dedifferentiation of thyroid tissue.

Authors:  Lars Kloth; Gazanfer Belge; Käte Burchardt; Siegfried Loeschke; Werner Wosniok; Xin Fu; Rolf Nimzyk; Salah A Mohamed; Norbert Drieschner; Volkhard Rippe; Jörn Bullerdiek
Journal:  BMC Clin Pathol       Date:  2011-11-04

7.  Lessons on Tumour Response: Imaging during Therapy with (177)Lu-DOTA-octreotate. A Case Report on a Patient with a Large Volume of Poorly Differentiated Neuroendocrine Carcinoma.

Authors:  Ulrike Garske; Mattias Sandström; Silvia Johansson; Dan Granberg; Hans Lundqvist; Mark Lubberink; Anders Sundin; Barbro Eriksson
Journal:  Theranostics       Date:  2012-05-09       Impact factor: 11.556

8.  Inhibition of microRNA-875-5p promotes radioiodine uptake in poorly differentiated thyroid carcinoma cells by upregulating sodium-iodide symporter.

Authors:  Y Tang; X Meng; X Yu; H Shang; S Chen; L Liao; J Dong
Journal:  J Endocrinol Invest       Date:  2019-10-14       Impact factor: 5.467

9.  The Effect of Diagnostic Absorbed Doses from 131I on Human Thyrocytes in Vitro.

Authors:  Zbigniew Adamczewski; Mariusz Stasiołek; Bolesław Karwowski; Marek Dedecjus; Daria Orszulak-Michalak; Anna Merecz; Przemysław W Śliwka; Bartosz Puła; Andrzej Lewiński
Journal:  Int J Mol Sci       Date:  2015-06-29       Impact factor: 5.923

Review 10.  Radionuclides in the management of thyroid cancer.

Authors:  J R Buscombe
Journal:  Cancer Imaging       Date:  2007-12-17       Impact factor: 3.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.